Anavex Life Sciences (AVXL) Current Deferred Revenue (2021 - 2025)
Anavex Life Sciences (AVXL) reported Current Deferred Revenue of $805000.0 for Q2 2025, down 12.21% on a YoY basis from $917000.0 in Q2 2024, and down 2.9% sequentially from $829000.0 in Q1 2025.
Anavex Life Sciences (AVXL) Current Deferred Revenue (2021 - 2025) Analysis & Trends
Anavex Life Sciences (AVXL) has 5 years of Current Deferred Revenue data on file, last reported at $805000.0 in Q2 2025.
- For the quarter ending Q2 2025, Current Deferred Revenue fell 12.21% year-over-year to $805000.0; the trailing twelve-month figure through Jun 2025 stood at $805000.0 (down 12.21% YoY), and the FY2024 full-year result was $842000.0, down 8.18% from the prior year.
- Current Deferred Revenue retreated to $805000.0 in Q2 2025, from $829000.0 in the prior quarter.
- In the past five years, Current Deferred Revenue ranged from a high of $917000.0 in Q3 2023 to a low of $443831.0 in Q2 2021.
- A 5-year average of $715188.1 and a median of $829000.0 in 2024 frame the typical range for Current Deferred Revenue.
- Across the five-year window, Current Deferred Revenue soared 106.61% in 2023 and dropped 12.21% in 2025, its largest moves.
- Tracing AVXL's Current Deferred Revenue over 5 years: stood at $443831.0 in 2021, then surged by 106.56% to $916763.0 in 2022, then gained by 0.03% to $917000.0 in 2023, then retreated by 9.6% to $829000.0 in 2024, then slipped by 2.9% to $805000.0 in 2025.
- Business Quant data shows AVXL's Current Deferred Revenue at $805000.0 in Q2 2025, $829000.0 in Q1 2025, and $829000.0 in Q4 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - |
| 10 | Anavex Life Sciences | 229.83 Mn | 98.08 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2025 | 805,000.00 |
| Mar 31, 2025 | 829,000.00 |
| Dec 31, 2024 | 829,000.00 |
| Sep 30, 2024 | 842,000.00 |
| Jun 30, 2024 | 917,000.00 |
| Mar 31, 2024 | 917,000.00 |
| Dec 31, 2023 | 917,000.00 |
| Sep 30, 2023 | 917,000.00 |
| Jun 30, 2023 | 916,763.00 |
| Mar 31, 2023 | 916,763.00 |
| Dec 31, 2022 | 916,763.00 |
| Sep 30, 2022 | 443,831.00 |
| Jun 30, 2022 | 443,831.00 |
| Mar 31, 2022 | 443,831.00 |
| Dec 31, 2021 | 443,831.00 |
| Sep 30, 2021 | 443,831.00 |
| Jun 30, 2021 | 443,831.00 |
| Mar 31, 2021 | 487,111.00 |